Back Back
Expert Think Tank on <i>EGFR</i>m NSCLC: Module

CE / CME

Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Pharmacists: 1.25 contact hours (0.125 CEUs)

Nurses: 1.25 Nursing contact hours

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits™

Released: September 30, 2022

Expiration: September 29, 2023

Edward B. Garon
Edward B. Garon, MD, MS
Xiuning Le
Xiuning Le, MD, PhD
Zofia Piotrowska
Zofia Piotrowska, MD
Mark A. Socinski
Mark A. Socinski, MD
Helena Yu
Helena Yu, MD
CME/CE Information

Activity

Progress
1
Course Completed
Claim Certificate

References

  1. Wu YL, Tsuobi M, He J, et al. Osimertinib in resected EGFR-mutated non-small cell lung cancer. N Engl J Med. 2020;383:1711-1723.
  2. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25:4691-4700.
  3. US Food and Drug Administration. FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations. fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations. Accessed September 6, 2022.
  4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
  5. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
  6. Durvalumab prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2021.
  7. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301-1311.
  8. Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naïve patients with advanced NSCLC. J Thorac Oncol. 2018;13:1138-1145.
  9. Pisters K, Kris MG, Gaspar LE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I-IIIA completely resected non-small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40:1127-1129.
  10. Chen RL, Sun LL, Cao Y, et al. Adjuvant EGFR-TKIs for patients with resected EGFR-mutant non-small cell lung cancer: a meta-analysis of 1,283 patients. Front Oncol. 2021;11:629394.
  11. Atezolizumab prescribing information. South San Francisco, CA: Genentech, Inc.; 2022.
  12. US Food and Drug Administration. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer. Accessed September 6, 2022.
  13. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomized, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
  14. Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585-4593.
  15. Osimertinib prescribing information. Waltham, MA: AstraZeneca Pharmaceuticals LP; 2022.
  16. Ahn MJ, Cho BC, Ou X, et al. Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial. J Thorac Oncol. 2022;17:718-723.
  17. Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30:839-844.
  18. Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-125.
  19. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with simertinib in untreated EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.
  20. Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16:205.
  21. Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:1655-1669.
  22. US Food and Drug Administration. FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC. fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc#:~:text=On%20May%2029%2C%202020%2C%20the,exon%2021%20(L858R)%20mutations. Accessed September 6, 2022.
  23. Nishio K, Seto T, Nishio M, et al. Ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated metastatic EGFR-mutated NSCLC: RELAY Japanese subset. JTO Clin Res Rep. 2021;2:100171.
  24. Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597:732-737.
  25. Afatinib prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2022.
  26. Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16:830-838.
  27. Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR Mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38:488-495.
  28. Yu HA, Suzawa K, Jordan E, et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR Kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin Cancer Res. 2018;24:3108-3118.
  29. Vokes NI, Chambers E, Nguyen T, et al. Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2022;17:779-792.
  30. Zhang Y, Zeng L, Zhang X, et al. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC. BMC Med. 2021;19:245.
  31. Nagasaka M, Zhu VW, Lim SM, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 2021;16:740-763.
  32. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-2247.
  33. Schoenfeld AJ, Chan JM, Kubota D, et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin Cancer Res. 2020;26:2654-2663.
  34. Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37:278-285.
  35. Suzawa K, Offin M, Schoenfeld AJ, et al. Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer. JCO Precis Oncol. 2019;3:PO.19.00011.
  36. Tepotinib prescribing information. Rockland, MA: EMD Serono, Inc.; 2021.
  37. Yu HA, Goldberg SB, Le X, et al. Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD.) Clin Lung Cancer. 2021;22:601-606.
  38. Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529-1539.
  39. Soria J-C, Wu Y-L, Nakagawa K, et al. Gefitnib plus chemotherapy versus placebo in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomized trial. Lancet Oncol. 2015;16:990-998.
  40. Yu HA, Sima CS, Huang J, et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8:346-351.
  41. Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558-1565.
  42. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288-2301.
  43. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909-1924.
  44. Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7:387-401.
  45. Lu S, Wu L, Jian Y, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022;23:1167-1179.
  46. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078-2092.
  47. White MN, Piper-Vallillo AJ, Gardner RM, et al. Chemotherapy plus immunotherapy versus chemotherapy plus bevacizumab versus chemotherapy alone in EGFR-mutant NSCLC after progression on osimertinib. Clin Lung Cancer. 2022;23:e210-e221.
  48. Hosomi Y, Morita S, Sugawara S. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38:115-123.
  49. Noronha V, Patil VM, Joshi A. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38:124-136.
  50. Kallergi G, Kontopodis E, Ntzfia A, et al. Effect of osimertinib on CTCs and ctDNA in EGFR mutant non-small cell lung cancer patients: The prognostic relevance of liquid biopsy. Cancers (Basel). 2022;14:1574.
  51. Yu HA, Ambrose H, Baik C. et al. ORCHARD osimertinib + savolitinib interim analysis: a biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib. Presented at: 2021 European Society for Medical Oncology Congress; September 16-21, 2021. Abstract 1239P.
  52. Jänne PA, Baik C, Su W, et al. Efficacy and safety of patritumab deruxtecan (HER3-Dxd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74-89.
  53. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19:2044-2056.
  54. Amivantamab prescribing information. Raritan, NJ: Janssen Biotech, Inc.; 2021.
  55. Ahn M-J, Han J-Y, Lee KH, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20:1681-1690.
  56. Bauml J, Chul Cho B, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naive EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9006.
  57. Shu CA, Goto K, Ohe Y, et al. Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. Presented at: 2022 American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 9006.
  58. Garon E, Johnson M, Lisberg A, et al. TROPION-PanTumor01: updated results from the NSCLC cohort of the phase 1 study of datopotamab deruxtecan in solid tumors. Presented at: 2021 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 8-14, 2021. Abstract MA03.02.
  59. Mobocertinib PI prescribing information. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2021.
  60. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391-3402.
  61. Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7:e214761.
  62. Le X, Cornelissen R, Garassino M, et al. Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 Trial. J Clin Oncol. 2022;40:710-718.
  63. Tsuboi M, Wu Y, Grohe C, et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA. Presented at: 2022 European Society for Medical Oncology Congress; September 9-13, 2021. Abstract LBA47.

BACK | NEXT
Claim Certificate